Although further pre-clinical studies should be conducted, strong similarities of tuft cell-like LCNEC to tuft cell-like SCLC may justify their eligibility for inclusion in future SCLC clinical studies, particularly trials including PARP inhibitors or co-inhibition of PARP and BCL2. This evidence concerns the gene BCL2 and small cell lung carcinoma.